IP Library Granted Patent US 9,765,360
Granted Patent B2
US 9,765,360 · App. 15/146,276 · Granted Sep 19, 2017

Linear donor constructs for targeted integration

Inventors: Russell DeKelver (Richmond, CA); Philip D. Gregory (Richmond, CA); Michael C. Holmes (Richmond, CA); Fyodor Urnov (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
C12N15/907C12N15/63C12N15/8213
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,765,360
App. No.
15/146,276
Granted
Sep 19, 2017
Kind
B2
Abstract

Disclosed herein are linear donor molecules comprising homology arms of 50-750 base pairs (e.g., 50-100 base pairs) flanking one or more sequences of interest. The donor molecules and/or compositions comprising these molecules can be used in methods for targeted integration of an exogenous sequence into a specified region of interest in the genome of a cell.

Claims (19)

1. A method for homology-dependent targeted integration of a sequence of interest into a region of interest in the genome of a cell, the method comprising the steps of:

(a) expressing a fusion protein in the cell, the fusion protein comprising a meganuclease or zinc finger protein DNA-binding domain and FokI cleavage domain or a cleavage half-domain, wherein the DNA-binding domain has been engineered to bind to a target site in the region of interest;

(b) contacting the cell with a donor polynucleotide comprising a linear donor nucleic acid molecule comprising homology arms of no more than 50 and 100 base pairs in length and a sequence of interest, wherein the homology arms flank the sequence of interest,

wherein binding of the fusion protein to the target site cleaves the genome of the cell in the region of the interest, thereby resulting in homology-dependent targeted integration of the sequence of interest into the genome of the cell.

2. A method for homology-dependent targeted integration of a sequence of interest into a cell, the method comprising:

(a) expressing a first fusion protein in the cell, the first fusion protein comprising a first meganuclease or zinc finger DNA-binding domain and a first FokI cleavage half-domain, wherein the first DNA-binding domain has been engineered to bind to a first target site in a region of interest in the genome of the cell;

(b) expressing a second fusion protein in the cell, the second fusion protein comprising a second meganuclease or zinc finger DNA-domain and a second FokI cleavage half domain, wherein the second zinc finger binding domain binds to a second target site in the region of interest in the genome of the cell, wherein the second target site is different from the first target site; and

(c) contacting the cell with a polynucleotide comprising a donor nucleic acid comprising a linear donor nucleic acid molecule comprising homology arms of no more than 50 and 100 base pairs in length and a sequence of interest, wherein the homology arms flank the sequence of interest;

wherein binding of the first fusion protein to the first target site, and binding of the second fusion protein to the second target site, positions the cleavage half-domains such that the genome of the cell is cleaved in the region of interest, thereby resulting in homology-dependent integration of the donor nucleic said into the genome of the cell.

3. The method of claim 1 , wherein at least one DNA-binding domain is a zinc finger binding domain.

4. The method of claim 1 , wherein at least one DNA-binding domain is a meganuclease DNA-binding domain.

5. The method of claim 1 , wherein the sequence of interest from the integrated donor nucleic acid expresses a polypeptide.

6. The method of claim 1 , wherein the sequence in interest from the integrated donor comprises a non-coding nucleic acid sequence.

7. The method of claim 1 , further comprising a cleavage domain from a meganuclease.

8. The method according to claim 1 , wherein the cell is arrested in the G2 phase of the cell cycle.

9. The method according to claim 1 , wherein at least one of the fusion proteins comprises an alteration in the amino acid sequence of the dimerization interface of the cleavage half-domain.

10. The method according to claim 1 , wherein the cell is a mammalian cell.

11. The method according to claim 1 , wherein the cell is a human cell.

12. The method according to claim 1 , wherein the cell is a plant cell.

Assignments (1)
CHANGE OF NAME Recorded Jul 21, 2017
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 043297/0470 →
Continuity (9)
Continuation 14699908 · Apr 29, 2015
Continuation 13134766 · Jun 16, 2011
Continuation 12386059 · Apr 13, 2009
Continuation 13134766 · Jun 16, 2011
Continuation In Part 11493423 · Jul 26, 2006
Provisional Application 61124047 · Apr 14, 2008
Provisional Application 60702394 · Jul 26, 2005
Provisional Application 60721054 · Sep 26, 2005
Related Publication 20160237457A1 · Aug 18, 2016